All In Biotech

Drug Trial Radar · NCT00908349

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Last checked: Nov 19, 2026Latest source record: May 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

214

Actual

Start

Jun 2009

Primary completion

Nov 2011

Study completion Nov 2011

Sponsor

Lead sponsor
Supernus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 25, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 66 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)

Conditions

  • Partial Epilepsy

Interventions

  • Oxcarbazepine XRDrug

    Open Label Study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Seizure RateTime frame: one year

Locations

58 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Northport, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Riverside, California

  • Site not named

    West Los Angeles, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Springfield, Illinois

  • Site not named

    Lexington, Kentucky

  • Site not named

    Bethesda, Maryland

  • Site not named

    Missoula, Montana

  • Site not named

    New York, New York

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Nashville, Tennessee

  • Site not named

    Baytown, Texas

  • Site not named

    Temple, Texas

  • Site not named

    Blagoevgrad, Bulgaria

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Rousse, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Varna, Bulgaria

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Greenfield Park, Quebec, Canada

  • Site not named

    Dubrovnik, Croatia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Aguascalientes, Mexico

  • Site not named

    Puebla City, Mexico

  • Site not named

    Col. Las Palmas, Chihuahua, Mexico

  • Site not named

    Col. Guillermina, Durango, Mexico

  • Site not named

    Guadalajara, Jalisco, Mexico

  • Site not named

    Zapopan, Jalisco, Mexico

  • Site not named

    Mexico City, Mexico City, Mexico

  • Site not named

    San Luis Potosí City, San Luis Potosí, Mexico

  • Site not named

    Giżycko, Poland

  • Site not named

    Katowice, Poland

  • Site not named

    Krakow, Poland

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.